Filtern
Volltext vorhanden
- ja (4)
Gehört zur Bibliographie
- ja (4)
Dokumenttyp
Sprache
- Englisch (4)
Schlagworte
- adolescents (2)
- anorexia nervosa (2)
- outcome (2)
- BDNF (1)
- BMI (1)
- VAL66MET polymorphism (1)
- adolescence anorexia nervosa (1)
- amenorrhea (1)
- bipolar disorder (1)
- body mass index (1)
- bone-mineral density (1)
- brain (1)
- children (1)
- clinical characteristics (1)
- deficit hyperactivity disorder (1)
- depressive symptoms (1)
- doublecortine-like (1)
- eating disorders (1)
- endophenotype (1)
- genes (1)
- genome-wide association (1)
- girls (1)
- increases (1)
- kinase (1)
- menarche (1)
- menstrual recovery (1)
- ovarian function (1)
- psychosis (1)
- recovery (1)
- resumption of menses (1)
- return (1)
- supplements (1)
- target weight (1)
- vitamin D (1)
- weight gain (1)
Institut
EU-Projektnummer / Contract (GA) number
- 245009 (1)
(1) Background: Evidence has accumulated that patients with anorexia nervosa (AN) are at higher risk for vitamin D deficiency than healthy controls. In epidemiologic studies, low 25(OH) vitamin D (25(OH)D) levels were associated with depression. This study analyzed the relationship between 25(OH)D serum levels in adolescent patients and AN and depressive symptoms over the course of treatment. (2) Methods: 25(OH)D levels and depressive symptoms were analyzed in 93 adolescent (in-)patients with AN from the Anorexia Nervosa Day patient versus Inpatient (ANDI) multicenter trial at clinic admission, discharge, and 1 year follow up. Mixed regression models were used to analyze the relationship between 25(OH)D levels and depressive symptoms assessed by the Beck Depression Inventory (BDI-II). (3) Results: Although mean 25(OH)D levels constantly remained in recommended ranges (≥50 nmol/L) during AN treatment, levels decreased from (in)patient admission to 1 year follow up. Levels of 25(OH)D were neither cross-sectionally, prospectively, nor longitudinally associated with the BDI-II score. (4) Conclusions: This study did not confirm that 25(OH)D levels are associated with depressive symptoms in patients with AN. However, increasing risks of vitamin D deficiency over the course of AN treatment indicate that clinicians should monitor 25(OH)D levels.